B-cell Activating Factor Polymorphisms in Rheumatoid Arthritis-Associated Atherosclerosis

Nikolaos Kintrilis, Adrianos Nezos, Evangelos A. Theodorou, M. Koutsilieris, Clio P. MavraganiMediterranean 2021 · DOI

Abstract

Rheumatoid Arthritis (RA) is a common chronic inflammatory disorder affecting 0.5-1% of the population, characterized by intense cellular activation and inflammation in the affected joints, ultimately leading to bone and cartilage destruction. Cardiovascular disease (CVD) is the leading cause of death among patients suffering from RA, with chronic inflammation and genetic background emerging as major predisposing factors. Although the pathogenetic events leading to an increased rate of atherosclerosis in the affected group are not precisely described, several genetic variations have been suggested as possible mediators of this process. The aim of the current research proposal is to investigate the role of B-cell activating factor (BAFF) variants in the pathogenesis of RA-related atherosclerosis. Stored DNA samples from the Biobank in the Department of Physiology of the Medical School of the University of Athens from RA individuals and healthy controls will be analyzed for polymorphisms of B-cell activating factor (BAFF) by polymeric chain reaction (PCR) based assays. Detection of plaque formation and calculation of the mean intima media thickness (mIMT) of the vessel wall will be performed in RA patients by using carotid and femoral artery ultrasonography. Complete personal and family history, biochemical and serological markers will be obtained from the RA group and associated with the genetic and IMT data. The results will be compared across the different subgroups in order to determine whether any particular genetic variants can act as prognostic markers for RA-related cardiovascular disease, giving eventually new insights to atherosclerotic processes in the context of chronic inflammatory diseases. Such a result would invariably lead to a possible new treatment approach and/or prevention method to benefit this group of patients.

Introduction

Rheumatoid Arthritis (RA) is a systemic autoimmune disease primarily recognized for its debilitating impact on synovial joints. However, the systemic nature of the inflammation involved in RA extends far beyond the musculoskeletal system. Epidemiological data indicates that patients with RA face a significantly higher risk of cardiovascular morbidity and mortality compared to the general population. In fact, cardiovascular disease (CVD) remains the primary cause of death in this patient group.

The accelerated atherosclerosis observed in RA is thought to be driven by a combination of traditional cardiovascular risk factors and the unique inflammatory environment of the disease. While chronic inflammation is a known catalyst for plaque formation, the specific genetic determinants that predispose certain RA patients to severe vascular damage remain elusive. One promising candidate for investigation is the B-cell activating factor (BAFF), a member of the tumor necrosis factor (TNF) ligand superfamily. BAFF is essential for B-cell survival and maturation; given the central role of B-cells in RA pathogenesis—including the production of autoantibodies like rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA)—variations in the BAFF gene may influence both joint disease and systemic vascular complications.

Research Objectives and Methodology

This research protocol, published in the Mediterranean Journal of Rheumatology, outlines a comprehensive study designed to evaluate the association between BAFF gene polymorphisms and subclinical atherosclerosis in RA patients.

Study Population

The study utilizes a well-characterized cohort from the Biobank of the Department of Physiology at the University of Athens. The participants include:

  • RA Group: 180 patients diagnosed according to the American College of Rheumatology (ACR) classification criteria.
  • Control Group: 180 age- and gender-matched healthy individuals of Caucasian origin.
  • Exclusion Criteria: To ensure data integrity, individuals under 18, pregnant women, and those with severe renal impairment (GFR < 30 ml/min) are excluded.

Genetic and Molecular Analysis

The core of the genetic investigation involves identifying single nucleotide polymorphisms (SNPs) in the BAFF gene using Polymerase Chain Reaction (PCR) based assays. To understand the functional impact of these variants, the researchers will also measure:

  • BAFF mRNA expression levels via Real-Time PCR.
  • Serum BAFF protein levels using Enzyme-Linked Immunosorbent Assay (ELISA).

Vascular Assessment

Subclinical atherosclerosis will be assessed non-invasively using high-resolution ultrasonography of the carotid and femoral arteries. The primary endpoints for vascular health are:

  1. Mean Intima Media Thickness (mIMT): A validated marker of early atherosclerotic changes.
  2. Plaque Presence: Identification of focal wall thickenings that indicate advanced atherosclerosis.

Statistical Approach

The study will employ multivariate statistical models (using SNPStats and SPSS) to correlate genetic data with clinical and vascular findings. This approach allows researchers to control for confounding variables such as age, smoking status, and traditional lipid profiles, isolating the independent effect of BAFF polymorphisms.

Discussion and Expected Insights

The hypothesis driving this study is that specific BAFF variants lead to increased BAFF expression, which in turn fuels the systemic inflammation responsible for arterial wall thickening. By linking genetic "blueprints" to physical vascular measurements, the study aims to provide a clearer picture of the "inflammatory-atherosclerosis" axis.

One of the most significant potential outcomes is the identification of BAFF polymorphisms as prognostic markers. If a specific genotype is strongly associated with high mIMT or plaque formation, clinicians could use genetic screening to identify high-risk RA patients early in their disease course. This would allow for more aggressive cardiovascular risk management, potentially including earlier intervention with statins or more intensive control of RA disease activity.

Furthermore, the study explores the relationship between BAFF and serological status (RF and ACPA). Since seropositive RA is often more aggressive, understanding how BAFF variants interact with these autoantibodies could reveal why certain subtypes of RA are more prone to cardiovascular complications.

Conclusion and Future Directions

While this protocol focuses on a Caucasian population, its findings could serve as a foundation for broader cross-ethnic studies. If the link between BAFF and atherosclerosis is confirmed, it may validate BAFF as a therapeutic target not just for joint inflammation, but for reducing cardiovascular risk. Existing BAFF-inhibiting therapies, currently used in other autoimmune conditions, might eventually find a role in the personalized treatment of Rheumatoid Arthritis to protect the heart as much as the joints.

This summary is based on the research protocol: "B-cell Activating Factor Polymorphisms in Rheumatoid Arthritis-Associated Atherosclerosis," Mediterranean Journal of Rheumatology, 2021.

Summary updated

Abstract

Rheumatoid Arthritis (RA) is a common chronic inflammatory disorder affecting 0,5-1% of the population, characterised by intense cellular activation and inflammation in the affected joints ultimately leading to bone and cartilage destruction. Cardiovascular disease is the leading cause of death among patients suffering from RA, with chronic inflammation and genetic background emerging as major predisposing factors. Although the pathogenetic events leading to an increased rate of atherosclerosis in the affected group are not precisely described, several genetic variations have been suggested as possible mediators of this process. The aim of the current research proposal is to investigate the role of B-cell activating factor (BAFF) variants in the pathogenesis of RA-related atherosclerosis. Stored DNA samples from the Biobank in the Department of Physiology of the Medical School of the University of Athens from RA individuals and healthy controls will be analysed for polymorphisms of B-cell activating factor (BAFF) by polymeric chain reaction (PCR) based assays. Detection of plaque formation and calculation of the mean intima media thickness (mIMT) of the vessel wall will be performed in RA patients by using carotid and femoral artery ultrasonography. Complete personal and family history, biochemical and serological markers will be obtained from the RA group and associated with the genetic and IMT data. The results will be compared across the different subgroups in order to determine whether any particular genetic variants can act as prognostic markers for RA-related cardiovascular disease giving eventually new insights to atherosclerotic processes in the context of chronic inflammatory diseases. Such a result would invariably lead to a possible new treatment approach and/or prevention method to benefit this group of patients.
BibTeX
@inproceedings{kintrilis2021b,
  author = {Nikolaos Kintrilis and Adrianos Nezos and Evangelos A. Theodorou and M. Koutsilieris and Clio P. Mavragani},
  title = {{B-cell Activating Factor Polymorphisms in Rheumatoid Arthritis-Associated Atherosclerosis}},
  booktitle = {Mediterranean},
  year = {2021},
  doi = {10.31138/mjr.32.2.179},
}
Figure